Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025
To participate in the conference call, interested parties must register in advance by clicking on . While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
To access the conference call via webcast, visit the 鈥淚nvestors鈥� section of Medpace鈥檚 website at . The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A supplemental slide presentation will also be available at the 鈥淚nvestors鈥� section of Medpace鈥檚 website prior to the start of the call.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace鈥檚 mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in
View source version on businesswire.com:
Investor Contact:
Lauren Morris
513.579.9911 x11994
[email protected]
Media Contact:
Michael Maley
513.579.9911 x12831
[email protected]
Source: Medpace Holdings, Inc.
